Business »  Topic »  Dr Reddy's falls nearly 2% after co clarifies on NuvaRing-USFDA issue; Citi cuts target by 6.5%

Dr Reddy's falls nearly 2% after co clarifies on NuvaRing-USFDA issue; Citi cuts target by 6.5%


The USFDA sends the applicant a CRL if the agency determines that it will not approve the application, or ANDA, in its present form for one or more reason

  • bselive
  • nselive

Shares of Dr Reddy's Laboratories fell 1.8 percent intraday on August 16 after the management issued a clarification after receiving a Complete Response Letter (CRL) from the US health regulator over its NuvaRing drug.

The stock had shed 1.8 percent on August 14 on street's expectations of a likely delay in the launch of NuvaRing drug. At 13:06 hours IST, the stock ...


Read the full text moneycontrol